Medtronic PLC (MDT) shares reached a 52-week high of $89.22, signaling a robust period for the medical device company amidst a fluctuating market. This peak reflects a notable turnaround from previous challenges, with the stock demonstrating a solid 1-year change with an increase of 6.37%. Investors and analysts are closely monitoring Medtronic's performance, as the company continues to innovate in the healthcare sector, potentially paving the way for sustained growth and investor confidence.
In other recent news, Medtronic Inc (NYSE:MDT). reported a 5.3% increase in revenue for the first quarter of fiscal 2025, surpassing expectations. The company's highest-grossing businesses saw an 8% growth, prompting an upward revision in full-year revenue and earnings per share guidance. Piper Sandler maintained its Overweight rating for Medtronic, while Goldman Sachs reiterated its Sell rating, citing continuous growth in operating expenses and uncertainties in other operating income and expenses. Meanwhile, Oppenheimer increased Medtronic's price target to $94, emphasizing the company's improved FY25 guidance and potential growth drivers. Mizuho also raised Medtronic's price target to $98, maintaining an Outperform rating, and highlighting the company's strong performance in its cardiovascular and diabetes sectors. On the other hand, Baird raised the price target to $90 but maintained a Neutral rating, expressing caution until clearer visibility on margin stabilization and a resurgence in EPS growth. These are among the recent developments for Medtronic Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.